

SHORT REPORT

Epidemiological typing of *Neisseria gonorrhoeae* and detection of markers associated with antimicrobial resistance directly from urine samples using next generation sequencing

R M A Graham, C J Doyle, A V Jennison

Public Health Microbiology,
Public and Environmental
Health, Forensic and Scientific
Services, Queensland
Department of Health,
Brisbane, Queensland,
Australia

Correspondence to

Dr R M A Graham, Public
Health Microbiology, Public
and Environmental Health,
Forensic and Scientific Services,
Queensland Department of
Health PO Box 594, Archerfield
QLD 4108, Australia; rikki.
graham@health.qld.gov.au

Received 14 October 2015

Revised 16 February 2016

Accepted 20 February 2016

Published Online First

11 March 2016

ABSTRACT

Objectives To investigate the potential for next generation sequencing (NGS) to be used directly on clinical specimens that have tested positive for *Neisseria gonorrhoeae* by nucleic acid amplification testing (NAAT), to generate information on epidemiological genotyping and antimicrobial resistance (AMR) markers. **Methods** DNA was extracted from 13 *N. gonorrhoeae* NAAT-positive urine specimens, enriched for microbial DNA and sequenced using the Ion Torrent PGM workflow. Sequences that aligned to the human genome were filtered out and the remaining sequences were de novo assembled. The resulting contigs were searched for regions of interest using Ridom SeqSphere. MLST and NG-MAST alleles were assigned according to the schemes at PubMLST.org and NG-MAST.net, respectively. **Results** In total, 11 of the 13 samples tested generated a sufficient number of *N. gonorrhoeae* sequence reads to provide full coverage of the genome at a depth of 6–130×. Complete MLST and NG-MAST sequence types could be generated for each of these samples. The presence of 10 different AMR markers was investigated, and both previously reported and novel mutations were identified in genes associated with reduced susceptibility to several antimicrobials.

Conclusions We found that sequencing the entire genome of *N. gonorrhoeae* directly from clinical samples is possible using NGS, and that multiple levels of *N. gonorrhoeae* typing information can be generated. As NAAT only testing becomes more common, this method could be used to detect both known and novel mutations associated with AMR and to generate genotyping information, supporting AMR and epidemiological surveillance in the absence of culturing.

INTRODUCTION

Neisseria gonorrhoeae, the causative agent of gonorrhoea, continues to be a major public health concern, due to a continued rise in the number of infections globally and increasing levels of antimicrobial resistance (AMR).¹ Over time, gonococci have developed resistance to previously used first-line antimicrobials such as penicillin, tetracycline, macrolides and fluoroquinolones, and isolates with decreased susceptibility to extended-spectrum cephalosporins have now been reported in several countries.² Antimicrobial sensitivity testing and surveillance of *N. gonorrhoeae* in the community using epidemiological typing methods such as

NG-MAST and MLST provide important information on transmission networks, disease clusters, and the emergence and spread of antimicrobial-resistant strains. In many countries, however, the diagnosis of gonorrhoea is now carried out predominately by nucleic acid amplification testing (NAAT), limiting the availability of isolates for epidemiological typing and phenotypic antimicrobial susceptibility testing. A number of molecular markers have been identified in *N. gonorrhoeae* for reduced susceptibility to antimicrobials; however, screening for these markers requires multiple molecular assays and may miss novel mutations. By sequencing the entire genome of *N. gonorrhoeae* directly from a clinical sample using next generation sequencing (NGS), typing information can be generated and both known and novel mutations associated with AMR identified, although the effect of any novel mutations on susceptibility to antimicrobials would require phenotypic analysis. We report on the potential for NGS performed directly on *N. gonorrhoeae*-positive clinical samples to generate data for AMR markers and epidemiological genotyping.

METHODS

A total of 13 deidentified urine-Cobas PCR media specimens were used in this study. These specimens were known to be positive for *N. gonorrhoeae* using the Roche Cobas 4800 CT/NG test, but no further information regarding the load of gonococcal DNA present in the samples was provided. DNA was extracted using the MasterPure DNA extraction kit (Epicentre, Madison Wisconsin, USA), according to the manufacturer's instructions. Total DNA was enriched for microbial DNA using the NEBNext microbiome kit (New England BioLabs, Ipswich, Massachusetts, USA). Extracted DNA was sheared to 300 bp using the Covaris S220 ultrasonicator and fragment libraries were prepared using the Ion Plus Fragment library kit and sequenced on an Ion Torrent PGM using the Ion PGM IC 200 Kit and 316v2 chips (Life Technologies, Carlsbad, California, USA) according to the manufacturer's instructions. Sequences that aligned to the human genome were removed and the remaining sequences were de novo assembled using Geneious R7. Sequences aligning to the *N. gonorrhoeae* FA1090 genome were uploaded to the European Nucleotide Archive under project



CrossMark

To cite: Graham RMA,
Doyle CJ, Jennison AV. *Sex
Transm Infect* 2017;**93**:65–
67.

accession PRJEB12537. This study was reviewed and approved by the Queensland Health Forensic and Scientific Services Human Ethics Committee (HEC15-010).

RESULTS AND DISCUSSION

To investigate the quality and abundance of gonococcal DNA present in the samples, sequences were mapped to the *N. gonorrhoeae* FA1090 reference genome (GenBank accession number: NC_002946) using CLC Genomics workbench 8. Enrichment of microbial DNA was found to be an essential step, as when DNA extracted from the samples was not enriched, fewer than 1% of sequences aligned to the *N. gonorrhoeae* genome. This number of reads was sufficient to identify the presence of *N. gonorrhoeae* in a sample using the K-mer Finder tool at the Center for Genomic Epidemiology (CGE) (<https://cge.cbs.dtu.dk/services/KmerFinder-2.0/>), but gave insufficient coverage of the genome to allow characterisation. Following enrichment for microbial DNA, in 11 of the 13 samples the percentage of sequences that aligned to the *N. gonorrhoeae* genome ranged from 2% to 43% of the total reads, which was sufficient to provide an average depth of coverage of the FA1090 genome of 6–130×. With the exception of the sample with only 6× coverage, sequences from all other samples provided greater than 10× coverage, and although 6× coverage is lower than ideal, the quality of the sequences generated from this sample was high, and robust typing information was still able to be generated. Enrichment for microbial DNA did not sufficiently improve the number of gonococcal sequence reads for two of the samples, so no further analysis was done. The presence of other *Neisseria* species in the specimens was excluded by *rplF* gene and K-mer analysis, which are methods used to accurately identify and discriminate between different

Neisseria species. To determine NG-MAST and MLST types, sequences from each sample were de novo assembled and the contigs were screened for the target loci using Ridom SeqSphere, which also assigned alleles and sequence types (STs) according to the schemes at NG-MAST.net and PubMLST.org, respectively. Each of the 11 samples had a unique NG-MAST ST, and none of the samples had more than one NG-MAST ST detected, which would have been indicative of a same site mixed infection. Novel *tbpB* sequences were identified for two samples, which were assigned new allele types and STs. The sample with 6× coverage across the genome had regions in the *porB* and *tbpB* genes with only 4× coverage, which is lower than the minimum coverage recommended by Ridom SeqSphere. However, there were no ambiguities in these regions and all four reads were identical at all positions so it is likely that the consensus sequences generated and thus the ST assigned were accurate. All seven MLST loci were found in each sample at greater than 5× coverage, and nine different MLST STs were present, as described in table 1. In addition to the standard MLST, the 20 locus eMLST (pubMLST.net) profiles could be determined for all samples except S7, which had insufficient coverage of the *pip* gene, demonstrating the potential for higher resolution genotyping to be performed using the data generated.

The assembled sequence data for each sample was investigated for the presence of mutations in eight genes associated with reduced gonococcal antimicrobial susceptibility (table 1) using Ridom SeqSphere. Additionally, the presence of acquired resistance genes was investigated using the ResFinder tool at CGE (<https://cge.cbs.dtu.dk/services/ResFinder-2.1/>). A number of AMR markers were identified in the samples, the most common (9/11) being the A39T amino acid substitution in MtrR. This mutation has been associated with low-level resistance to

Table 1 NG-MAST and MLST sequence types, and molecular antimicrobial resistance markers identified in gonococcal DNA extracted from clinical samples

Sample	Polymorphism in										Presence of	
	NG-MAST	MLST	<i>mtrR</i> *†‡§	<i>penB</i> *†	<i>penA</i> genotype*†	<i>rpsJ</i> §	<i>gyrA</i> ¶	<i>parC</i> ¶	<i>ponA</i> *	23S rRNA gene‡	Penicillinase-encoding plasmid*	TetM-encoding plasmid§
S1	9920	7363	A39T	A121G	II	WT	WT	WT	L421P	WT	No	No
S2	8709	9363	A39T	WT	II	V57M	WT	WT	WT	WT	No	No
S3	21	1579	Deletion of A**	G120K A121G	IX (D345a, A501V, P551L)	V57M	WT	WT	L421P	C2611T (4)††	No	No
S4	7138	11 430‡‡	A39T	WT	II	WT	WT	WT	WT	WT	No	No
S5	12 424‡‡	11 431‡‡	A39T	WT	II	V57M	S91F, D95A	E91G	WT	WT	Yes	No
S6	9654	11 428	A39T	WT	II	V57M	WT	WT	WT	WT	No	No
S7	12 425‡‡	8134	A39T	A121G	II	V57M	WT	WT	WT	WT	Yes	Yes
S8	4822	1901	Deletion of A	G120K A121N	XXXIV (Mosaic allele)	V57M	S91F, D95G	S87R	L421P	C2611T (2)	No	No
S9	10 558	9363	A39T	WT	II	V57M	WT	WT	WT	WT	No	No
S10	9909	7359	A39T	WT	II	WT	WT	WT	WT	WT	No	No
S11	4186	7359	A39T	WT	II	WT	WT	WT	WT	WT	No	No

*Associated with decreased susceptibility/resistance to penicillin.

†Associated with decreased susceptibility to cephalosporins.

‡Associated with decreased susceptibility to azithromycin.

§Associated with decreased susceptibility/resistance to tetracycline.

¶Associated with decreased susceptibility to quinolones.

**Contains an A deletion in the 13 bp inverted repeat region of the *mtrR* promoter.

††Parentheses indicate number of alleles with this mutation.

‡‡STs not previously identified.

STs, sequence types; WT, wild type.

macrolides and β -lactam antibiotics,² and decreased susceptibility to quinolones when present in conjunction with the MtrR G45D mutation, but reportedly has limited effect on susceptibility when present on its own.³ More strongly linked to antibiotic resistance is an adenine deletion in the promoter of *mtrR*,⁴ which was present in two specimens, S3 and S8. These specimens also had several other AMR markers and characteristics suggestive of multiple drug resistance. S3 had the type IX *penA* allele, which is not mosaic in structure but has D345a, A501V and P551L mutations, which are associated with reduced susceptibility to ceftriaxone when present in conjunction with the G120K, A121D mutations in *penB* that were also present in this sample.⁵ S8 was determined to be MLST ST1901 and NG-MAST ST4822. *N. gonorrhoeae* with MLST ST1901 form a globally distributed multidrug-resistant gonococcal clone,⁶ and NG-MAST ST4822 has been associated with resistance to multiple drugs in South Africa,⁷ a phenotype also seen in many Queensland NG-MAST ST4822 isolates (unpublished data). Specimen S8 had the type XXXIV *penA* mosaic allele, the L421P mutation in *ponA*, and the G120K and A121N mutations in *penB*, AMR markers that are identical to those described in the South African NG-MAST ST4822 isolates.⁷ Both S3 and S8 also had mutations in *gyrA* and *parC*, *rpsJ* and the 23S rRNA genes, which are associated with reduced susceptibility to quinolones,⁸ tetracycline⁹ and azithromycin, respectively.¹⁰ Penicillinase-producing plasmid sequences were present in two specimens, and TetM-encoding plasmid sequences were identified in one specimen. Given these specimens were from a non-sterile site and organisms other than *N. gonorrhoeae* will be present, it is possible that the AMR markers detected do not belong to *N. gonorrhoeae*, and care should be taken in interpreting these results. However, the chromosomal markers identified in this study have been used in previous studies as targets for real-time PCR performed directly on clinical samples, and the single-nucleotide polymorphisms present have a high specificity for *N. gonorrhoeae*.^{11–12} As *N. gonorrhoeae* was not cultured from these specimens, phenotypic antimicrobial sensitivity testing data were not available, so we are unable to confirm if the genotypic markers detected contribute to the AMR profile of *N. gonorrhoeae* present in the samples; however, these markers have been shown to be good predictors of reduced susceptibility to antimicrobials in several studies (reviewed in ref. 2). Furthermore, the relationship between genotype and phenotype with regard to antimicrobial sensitivity is complex and involves interactions between the products of several genes. In many cases, multiple mutations are necessary to produce reduced susceptibility to a given drug.²

In this study, sequencing all gonococcal DNA present in *N. gonorrhoeae* NAAT-positive specimens by NGS could, in the majority of samples, generate extensive information on AMR markers and genotypes. This approach, while not yet cost effective for routine public health surveillance, does demonstrate a means to produce valuable information on potential AMR where a culture is not available and replaces the need for multiple molecular tests targeting individual markers. The ability to identify novel mutations that may have an effect on antimicrobial sensitivity is also highly beneficial. In several of the specimens tested in this study, previously undescribed mutations in AMR marker genes were identified. These include a R44H mutation in *mtrR* and A59T mutation in *gyrA*. Whether these mutations have any effect on antimicrobial sensitivity cannot be inferred from this study, but they may warrant further

investigation by phenotypic testing. The specimens provided in this study were identified as *N. gonorrhoeae* positive by NAAT only, meaning that there were no matched bacterial isolates available to confirm the results generated by NGS. This is a limitation of the study to date, with further validation of the method using *N. gonorrhoeae* isolates intended.

This study has demonstrated that NGS can be used to generate extensive *N. gonorrhoeae* typing information directly from clinical samples using simple bioinformatics tools. Using this technology, we were able to identify multiple AMR markers and determine NG-MAST and MLST ST in *N. gonorrhoeae*-positive samples diagnosed by NAAT only. As NAAT only testing for *N. gonorrhoeae* becomes more common, the ability to perform epidemiological typing and antimicrobial sensitivity testing directly on clinical samples will be vital to ensure this valuable information can continue to be collected.

Handling editor Jackie A Cassell

Acknowledgements The authors acknowledge Sullivan Nicolaides Pathology for providing the specimens used in this study.

Contributors RMAG designed the study, performed testing and data analysis, and wrote the paper. CJD performed data collection and analysis. AVJ advised on study design, data analysis and manuscript preparation.

Competing interests None declared.

Ethics approval This study was approved by the Queensland Health Forensic and Scientific Services Human Ethics Committee, approval number HEC15-010.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 WHO. Global action plan to control the spread and impact of antimicrobial resistance in *Neisseria gonorrhoeae*. 2012. http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf (accessed Aug 2015).
- 2 Unemo M, Shafer WM. Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future. *Clin Microbiol Rev* 2014;27:587–613.
- 3 Dewi BE, Akira S, Hayashi H, et al. High Occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant *Neisseria gonorrhoeae*. *Sex Transm Dis* 2004;31:353–9.
- 4 Lee SG, Lee H, Jeong SH, et al. Various *penA* mutations together with *mtrR*, *porB* and *ponA* mutations in *Neisseria gonorrhoeae* isolates with reduced susceptibility to cefixime or ceftriaxone. *J Antimicrob Chemother* 2010;65:669–75.
- 5 Whitley DM, Goire N, Lambert SB, et al. Reduced susceptibility to ceftriaxone in *Neisseria gonorrhoeae* is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. *J Antimicrob Chemother* 2010;65:1615–18.
- 6 Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant *Neisseria gonorrhoeae* in France: novel *penA* mosaic allele in a successful international clone causes treatment failure. *Antimicrob Agents Chemother* 2012;56:1273–80.
- 7 Lewis DA, Srirottan C, Müller EE, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant *Neisseria gonorrhoeae* infection in South Africa and association with cefixime treatment failure. *J Antimicrob Chemother* 2013;68:1267–70.
- 8 Zhou W, Du W, Cao H, et al. Detection of *gyrA* and *parC* mutations associated with ciprofloxacin resistance in *Neisseria gonorrhoeae* by use of oligonucleotide biochip technology. *J Clin Microbiol* 2004;42:5819–24.
- 9 Hu M, Nandi S, Davies C, et al. High-level chromosomally mediated tetracycline resistance in *Neisseria gonorrhoeae* results from a point mutation in the *rpsJ* gene encoding ribosomal protein S10 in combination with the *mtrR* and *penB* resistance determinants. *Antimicrob Agents Chemother* 2005;49:4327–34.
- 10 Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in *Neisseria gonorrhoeae* as a result of a single point mutation in the 23S rRNA genes. *Antimicrob Agents Chemother* 2010;54:3812–16.
- 11 Nicol M, Whitley D, Nulsen M, et al. Direct detection of markers associated with *Neisseria gonorrhoeae* antimicrobial resistance in New Zealand using residual DNA from the Cobas 4800 CT/NG NAAT assay. *Sex Transm Infect* 2015;91:91–3.
- 12 Peterson SW, Martin I, Demczuk W, et al. Molecular Assay for Detection of Ciprofloxacin Resistance in *Neisseria gonorrhoeae* Isolates from Cultures and Clinical Nucleic Acid Amplification Test Specimens. *J Clin Microbiol* 2015;53:3606–8.